Citations

Clear

16280 citation(s) found for "Yu, David".

Personalized Platelet Protocols: Progress, Pitfalls, and Potential
Kallmes, David F. , Altschul, Dorothea

Mayo Clinic

Radiology | March 18, 2025 | Volume: 314 | Issue: 3 | Pages: No page available

10.1148/radiol.250488 | PMID 40100024 Get It

Human Platelet Extract (Plated) Hair Serum for Hair Health Improvement: A Double-blind, Placebo-controlled Clinical Study
Weir, David , Wyles, Saranya P. , Eaton-Jankov, Laura, Secic, Michelle, Bell, Michaela , Rohrich, Rod J., Wyles, Saranya, Behfar, Atta , Vyas, Krishna S.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | March 18, 2025 | Volume: 13 | Issue: 3 | Pages: e6562

10.1097/gox.0000000000006562 | PMID 40104384 Get It

Background: The primary aim of this study was to demonstrate the benefits of topical human platelet exosome extract (HPE) (plated) hair serum for improving hair and scalp health in participants with self-perceived thinning hair. Methods: This single-center, placebo-controlled, double-blind study enrolled 39 healthy men and women 18–65 years of age with self-perceived thinning hair. Participants applied either HPE for 9 months or a topical placebo for 6 months with the option to cross over to HPE at 6 months for an additional 3 months. End points included improvements in the global aesthetic appearance of hair, as assessed by a blinded live evaluator; participant-reported outcomes; hair trichoscopy; and independent physician photograph evaluations. Safety data included monitoring for adverse events. Results: Blinded live evaluator assessments demonstrated statistically significant improvements in the global aesthetic appearance of hair for volume/fullness, density, scalp coverage, and appearance, with all P values less than 0.0001 within the HPE group and statistical improvement over the control at months 3 and 6 for volume/fullness, density, and scalp coverage. Participant-reported outcomes for within-group changes for HPE were statistically significant for all hair health parameters, including density, volume fullness, scalp coverage, scalp health, thickness, amount, quality, color, dryness, strength, and overall health of the hair. Hair trichoscopy analyses were significantly improved from baseline within the HPE group. Independent physician photography review demonstrated greater improvements within the HPE group. No adverse effects were observed. Conclusions: This study demonstrates that topical HPE (plated) hair serum with Renewosome technology significantly improves hair and scalp health and is safe and well tolerated.
The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti‐TNF Therapy: A Multicentre Study
Munir, Javeria, Parlow, Simon , Sambhi, Gagan Deep Singh, Reid, Jacqueline, Yanofsky, Russell , Alenezi, Talal , Meserve, Joseph , Yeh, Kuan‐Hung, Becker, Brenda, Lahijanian, Zubin, Eddin, Anas Hussam, Mallick, Ranjeeta , Rosenfeld, Greg , Bessissow, Ali, Bruining, David H. , Macdonald, Blair , Singh, Siddharth, Parlow, Simon , Jairath, V , McCurdy, Jeffrey D , Yeh, Kuan‐Hung, Ramsay, Tim , Bessissow, Talat , Jairath, Vipul , Macdonald, Blair

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 18, 2025 | Volume: 61 | Issue: 10 | Pages: 1671-1679

10.1111/apt.70081 | PMID 40098436 Get It

ABSTRACTBackground and AimsWe aimed to assess the impact of setons on perianal fistula outcomes in patients with perianal fistulising Crohn's disease (PFCD) treated with anti‐TNF therapy.MethodsWe included patients treated with their first anti‐TNF therapy for PFCD after undergoing a pelvic MRI between 2005 and 2022 from 6 North American centres. Our exposure was one or more setons at the time of anti‐TNF therapy. Our primary outcome was major adverse fistula outcome (MAFO), a composite of repeat local surgical intervention, hospitalisation, or faecal diversion for PFCD, and our secondary outcome was fistula remission defined clinically. We used 1:1 cardinality matching and propensity score weighting to control for fistula severity based on centrally read MRIs, luminal characteristics, and concomitant therapies.ResultsOur analysis included 221 patients: 81 with setons and 140 without setons. After cardinality matching, our cohorts were balanced (standardised difference < 0.1 for all covariates). Patients with setons had similar rates of MAFO (HR 1.23; 95% CI, 0.68–2.21) and fistula remission at 6 months (OR, 0.81; 95% CI, 0.41–1.59) and 12 months (OR, 0.63; 95% CI, 0.31–1.27) compared to patients without setons. Our results remained stable when analysed by propensity score weighting and in a sensitivity analysis of patients who underwent an exam under anaesthesia. In patients with abscesses, there were lower rates of MAFO (HR, 0.49; 95% CI, 0.19–1.25) but not statistically significant in patients with setons.ConclusionsIn this multicentre, setons were not associated with improved fistula outcomes. Future prospective controlled studies are warranted.
Magnetization transfer imaging using non‐balanced SSFP at ultra‐low field
Balaji, Sharada , Wiley, Neale, Dvorak, Adam , Padormo, Francesco , Teixiera, Rui P. A. G., MacKay, Alex L. , Wood, Tobias , Cassidy, Adam R. , Vavasour, Irene M. , Williams, Steven , Deoni, Sean , Ljungberg, Emil , Kolind, Shannon , Wood, Tobias , Ljungberg, Emil , Kollind, Shannon H , Poorman, Megan , Traboulsee, Anthony , Li, David K.B.

Mayo Clinic

Magnetic Resonance in Medicine | March 17, 2025 | Volume: 94 | Issue: 2 | Pages: 602-614

10.1002/mrm.30494 | PMID 40096549 Get It

Abstract Purpose Ultra‐low field MRI scanners have the potential to improve health care delivery, both through improved access in areas where there are few MRI scanners and allowing more frequent monitoring of disease progression and treatment response. This may be particularly true in white matter disorders, including leukodystrophies and multiple sclerosis, in which frequent myelin‐sensitive imaging, such as magnetization transfer (MT) imaging, might improve clinical care and patient outcomes. Methods We implemented an on‐resonance approach to MT imaging on a commercial point‐of‐care 64 mT scanner using a non‐balanced steady‐state free precession sequence. Phantom and in vivo experiments were used to evaluate and optimize the sequence sensitivity and reproducibility, and to demonstrate in vivo performance and inter‐site reproducibility. Results From phantom experiments, T 1 and T 2 effects were determined to have a negligible effect on the differential MT weighting. MT ratio (MTR) values in white matter were 23.1 ± 1.0% from 10 healthy volunteers, with an average reproducibility coefficient of variation of 1.04%. Normal‐appearing white matter MTR values in a multiple sclerosis participant (21.5 ± 6.2%) were lower, but with a similar spread of values, compared to an age‐matched healthy volunteer (23.3 ± 6.2%). Conclusion An on‐resonance MT imaging approach was developed at 64 mT that can be performed in as little as 4 min. A semi‐quantitative myelin‐sensitive imaging biomarker at this field strength is available for assessing both myelination and demyelination.
Genomic Screening at a Single Health System
Savatt, Juliann M. , Sturm, Amy C. , McCormick, Cara Z., Nixon, Michelle Pistner , Rolston, David D.K. , Wain, Karen E. , Willard, Huntington F. , Faucett, W. Andrew , Ledbetter, David H., Buchanan, Adam H. , Martin, Christa L., Strande, Natasha T. , Sturm, Amy C , Kelly, Melissa , Williams, Marc S , Martin, Christa L.

Mayo Clinic

JAMA Network Open | March 17, 2025 | Volume: 8 | Issue: 3 | Pages: e250917

10.1001/jamanetworkopen.2025.0917 | PMID 40094662 Get It

Importance Completion of the Human Genome Project prompted predictions that genomics would transform medicine, including through genomic screening that identifies potentially medically actionable findings that could prevent disease, detect it earlier, or treat it better. However, genomic screening remains anchored in research and largely unavailable as part of routine care. Objective To summarize 11 years of experience with genomic screening and explore the landscape of genomic screening efforts. Design, Setting, and Participants This cohort study was based in Geisinger’s MyCode Community Health Initiative, a genomic screening program in a rural Pennsylvania health care system in which patient-participants exomes are analyzed. Main Outcomes and Measures Genomic screen-positive rates were evaluated and stratified by condition type (cancer, cardiovascular, other) and US Centers for Disease Control and Prevention (CDC) Tier 1 designation. The proportion of participants previously unaware of their genomic result was assessed. Other large-scale population-based genomic screening efforts with genomic results disclosure were compiled from public resources. Results A total of 354 957 patients participated in Geisinger’s genomic screening program (median [IQR] age, 54 [36-69] years; 194 037 [59.7%] assigned female sex at birth). As of June 2024, 175 500 participants had exome sequencing available for analysis, and 5934 participants (3.4%) had a pathogenic variant in 81 genes known to increase risk for disease. Between 2013 and July 2024, 5119 results were disclosed to 5052 eligible participants, with 2267 (44.2%) associated with risk for cardiovascular disease, 2031 (39.7%) with risk for cancer, and 821 (16.0%) with risk for other conditions. Most results (3040 [59.4%]) were in genes outside of those with a CDC Tier 1 designation. Nearly 90% of participants (4425 [87.6%]) were unaware of their genomic risk prior to disclosure. In a survey of large-scale biobanks with genomic and electronic health record (EHR) data, only 25.0% (6 of 24) disclosed potentially actionable genomic results. Conclusions and Relevance In this large, genomics-informed cohort study from a single health system, 1 in 30 participants had a potentially actionable genomic finding. However, nearly 90% were unaware of their risk prior to screening, demonstrating the utility of genomic screening in identifying at-risk individuals. Most large-scale biobanks with genomic and EHR data did not return genomic results with potential medical relevance, missing opportunities to significantly improve genomic risk ascertainment for these individuals and to perform longitudinal studies of clinical and implementation outcomes in diverse settings.
Amyloid PET in Sporadic Early‐ Versus Late‐Onset Alzheimer's Disease: Comparison of the LEADS and ADNI
Lagarde, Julien , Blazhenets, Ganna , Zhang, J. , Eloyan, Ani , Thangarajah, Maryanne, Taurone, Alexander, Allen, Isabel Elaine , Soleimani‐Meigooni, David N. , Zeltzer, Ehud , Windon, Charles , Raya, Maison Abu , Smith, Karen, Shankar, Ranjani , Amuiri, Alinda, Rocha, Salma, Hammers, Dustin B. , Dage, Jeffrey L. , Kirby, Kala, Aisen, Paul, Koeppe, Robert, Landau, Susan, Carrillo, María C. , Touroutoglou, Alexandra , Brickhouse, Michael , Raman, Rema , Day, Gregory S. , Duara, Ranjan, Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Grant, Ian , Rogalskı, Emily , Johnson, Erik C. B. , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Apostolova, Liana G. , Joie, Renaud La , Rabinovici, Gil D. , Blazhenets, Ganna , Soleimani-Meigooni, David , Zeltzer, Ehud , Windon, Charles , Abu Raya, Maison , Vrillon, Agathe , Nudelman, Kelly N , Vemuri, Prashanthi , Day, Gregory S , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon , Wingo, Thomas S , La Joie, Renaud , Rabinovici, Gil D , Dage, Jeffrey L , Maiti, Piyush , Schonhaut, Daniel R. , Hammers, Dustin B , Nudelman, Kelly , Kirby, Kala, Vemuri, Prashanthi , Beckett, Laurel , Atri, Alireza , Honig, Lawrence S. , Jones, David T., Womack, Kyle , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Annals of Neurology | March 17, 2025 | Volume: 98 | Issue: 2 | Pages: 236-248

10.1002/ana.27233 | PMID 40091774 Get It

Objective Early‐onset Alzheimer's disease (EOAD) and late‐onset Alzheimer's disease (LOAD) differ in many respects. Here, we address the issue of possible differences in fibrillar amyloid pathology as measured by positron emission tomography (PET), which remains unresolved due to the lack of large‐scale comparative studies. Methods Three hundred ninety‐nine cognitively impaired participants younger than 65 years of age from the multicenter Longitudinal Early‐onset Alzheimer's Disease Study (LEADS) and 450 cognitively impaired participants older than 65 years from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent clinical assessment, brain magnetic resonance imaging (MRI), and amyloid PET and were included in this study. We compared amyloid PET outcomes (positivity rate based on visual read and quantified tracer uptake expressed as Centiloids [CLs]) between the 2 cohorts and studied their association with age, sex, APOE genotype, and cognition. Results The amyloid positivity rate was higher in LEADS (78%, 95% confidence interval [CI] = 74–82) than in ADNI (71%, 95% CI = 67–75, p = 0.02). Lower Mini‐Mental State Examination (MMSE) and APOE4 genotype increased the odds of amyloid positivity in both cohorts. Visually positive scans had higher CLs in LEADS (EOAD, mean = 95.3 ± 26.1) than in ADNI (LOAD, mean = 80.9 ± 36.8, p < 0.0001), predominantly in parietal cortex/precuneus, superior temporal, and frontal cortices. In amyloid‐positive patients, (1) CLs were higher in female patients in both cohorts; (2) APOE4 carriership was associated with lower CLs in EOAD, which was not observed in LOAD; and (3) correlations between CLs and MMSE scores were significantly stronger in EOAD than in LOAD. Interpretation Differences in the burden of amyloid pathology may contribute to differences in clinical and anatomic patterns in sporadic EOAD and LOAD, and have implications for optimizing therapeutic strategies in each group. ANN NEUROL 2025;98:236–248
Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition
Yin, Jinhu , Leduc, Charles , Sholl, Lynette M. , McElderry, John, Hartman, Caleb , Rosenbaum, Jennifer, Colón-Matos, Frank J. , Miraftab, Mona , Caporaso, Neil E. , Wong, Maria Pik , Leung, Kin Chung, Hsiung, Chao A. , Chen, Chih-Yi, Edell, Eric S. , Santamaría, Jacobo Martínez, Mańczuk, Marta , Mukeria, Anush, Shangina, Oxana , Заридзе, Давид , Mates, Dana, Milosavljević, Saša , Savić, Milan , Gaborieau, Valérie , Hofman, Paul L. , Yang, Lixing , Shi, Jianxin , Brown, Kevin M. , Rothman, Nathaniel , Choi, Jiyeon , Lan, Qing , Wedge, David C. , Landi, Maria Teresa , Chen, Chih‐Yi , Manczuk, Marta , Chen, Chih-Yi , Leduc, Charles , Zhang, Tongwu , Zhao, Wei , Wirth, Christopher, Díaz‐Gay, Marcos , Cecati, Monia , Marchegiani, Francesca , Hoang, Phuc H. , Baine, Marina K , Travis, William D. , Joubert, Philippe , Sang, Jian , Klein, Alyssa , Khandekar, Azhar , Saha, Monjoy , Lee, Olivia W. , Jones, Kristine , Santamaría, Jacobo Martínez, Schabath, Matthew B. , Yendamuri, Sai S , Lissowska, Jolanta , Świątkowska, Beata , Holcátová, Ivana , Milosavljevic, Sasa , Bossé, Yohan , Gould Rothberg, Bonnie E , Christiani, David C. , Brennan, Paul Martin , Liu, Geoffrey , Hofman, Paul , Homer, Robert , Yang, Soo-Ryum , Pesatori, Angela C , Consonni, Dario , Zhu, Bin , Chanock, Stephen Jacob , Alexandrov, Ludmil B. , Cardelli, Maurizio , Nowak, Martin A.

Mayo Clinic

No container title available | March 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.14.643063 | PMID 40161734 Get It

ABSTRACT Understanding lung cancer evolution can identify tools for intercepting its growth. In a landscape analysis of 1024 lung adenocarcinomas (LUAD) with deep whole-genome sequencing integrated with multiomic data, we identified 542 LUAD that displayed diverse clonal architecture. In this group, we observed an interplay between mobile elements, endogenous and exogenous mutational processes, distinct driver genes, and epidemiological features. Our results revealed divergent evolutionary trajectories based on tobacco smoking exposure, ancestry, and sex. LUAD from smokers showed an abundance of tobacco-related C:G>A:T driver mutations in KRAS plus short subclonal diversification. LUAD in never smokers showed early occurrence of copy number alterations and EGFR mutations associated with SBS5 and SBS40a mutational signatures. Tumors harboring EGFR mutations exhibited long latency, particularly in females of European-ancestry (EU_N). In EU_N, EGFR mutations preceded the occurrence of other driver genes, including TP53 and RBM10. Tumors from Asian never smokers showed a short clonal evolution and presented with heterogeneous repetitive patterns for the inferred mutational order. Importantly, we found that the mutational signature ID2 is a marker of a previously unrecognized mechanism for LUAD evolution. Tumors with ID2 showed short latency and high L1 retrotransposon activity linked to L1 promoter demethylation. These tumors exhibited an aggressive phenotype, characterized by increased genomic instability, elevated hypoxia scores, low burden of neoantigens, propensity to develop metastasis, and poor overall survival. Re-activated L1 retrotransposition-induced mutagenesis can contribute to the origin of the mutational signature ID2, including through the regulation of the transcriptional factor ZNF695 , a member of the KZFP family. The complex nature of LUAD evolution creates both challenges and opportunities for screening and treatment plans.
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Shah, Meera , Hung, Kevin , Baranwal, Anmol , Al‐Kali, Aref , Toop, Carla , Greipp, Patricia T. , Brown, Anna , Shah, Syed Naseem, Khanna, Shreyas, Ladon, Dariusz, Gannamani, Vedavyas, Begna, Kebede H. , Price, Zoe, Rud, Danielle, Litzow, Mark R. , Bardy, Peter, Badar, Talha , Kumar, Sharad , Patnaik, Mrinal M. , Foran, James M. , He, Rong , Gangat, Naseema , Scott, Hamish S. , Mangaonkar, Abhishek A. , Hahn, Christopher N , Tefferi, Ayalew , Hiwase, Devendra , Shah, Mithun V , Kutyna, Monika M , Al-Kali, Aref , Toop, Carla , Greipp, Patricia T , Brown, Anna L , Begna, Kebede , Litzow, Mark R. , Hogan, William J , Badar, Talha , Kumar, Sharad , Patnaik, Mrinal , He, Rong , Gangat, Naseema , Scott, Hamish , Arana Yi, Cecilia , Hahn, Christopher , Arber, Daniel A , Kok, Chung H , Hiwase, Devendra , Baranwal, Anmol , Hung, Kevin , Kutyna, Monika , Chen, Dong , Price, Zoe K. , Hogan, William J. , Yeung, David , Yi, Cecilia Arana , Alkhateeb, Hassan B. , THOMAS, DANIEL W. , Orazi, Attilio , Arber, Daniel A. , Kok, Chung Hoow

Mayo Clinic

Blood Advances | March 14, 2025 | Volume: 9 | Issue: 13 | Pages: 3370-3380

10.1182/bloodadvances.2024015238 | PMID 40085954 Get It

Abstract This retrospective analysis aimed to provide evidence-based risk stratification of TP53-mutated (TP53mut) myeloid neoplasms (MNs). Of 580 MNs harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92 (15.9%), and 75 (12.9%) were classified as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) with low blasts (MDS-LB), MDS with excess blasts (MDS-EB)-2, and -EB1 according to the revised fourth edition of the World Health Organization (WHO) classification, respectively. Hierarchical analysis identified the following 4 risk groups with distinct survival: (1) MDS-LB, (2) MDS-EB1/EB2/AML VAF &lt;10%, (3) MDS-EB1/EB2 VAF ≥10%, and (4) AML VAF ≥10%. We next evaluated the impact of allelic status, VAF, and complex karyotype (CK). In our cohort, the significance of biallelic status was limited to MDS with &lt;5% blasts and not for blasts 5% to 9%, as proposed by the International Consensus Classification (ICC), or 5% to 19%, as proposed by the fifth edition of the WHO (WHO-5). MDS-EB1 and -EB2 with VAF ≥10% had comparable survival (9.6 vs 7.2 months; P = .12), regardless of allelic status. Contrary to the ICC proposal, MDS-EB1/EB2 with VAF &lt;10% and CK had poor survival compared with those without CK, comparable to MDS-EB1/EB2 with VAF ≥10% (5.6 vs 26.2 vs 6.3 months; P = .003). Survival of TP53mut AML was poor (median 3.9 months) regardless of allelic/CK status. Thus, using ICC or WHO-5 may underestimate prognosis of MDS with blasts 5% to 19% and 5% to 9%, respectively. Collectively, the hierarchical model acknowledges poor survival of 91.9% TP53mut MDS and AML compared with 36.5% and 80.7% by WHO-5 and ICC, respectively.
Trends and Outcomes Following Percutaneous Coronary Intervention in Patients With Myeloproliferative Neoplasms: Insights From National Database
Ang, Song Peng , Chia, Jia Ee , Krittanawong, Chayakrit , Piana, Robert N. , Lee, Kwan , Ayoub, Chadi , Pineda, JR Exequiel, Song, David , Mukherjee, Debabrata , Lee, Kwan S , Ang, Song P , Mukherjee, Debabrata , Ayoub, Chadi

Mayo Clinic

Catheterization and Cardiovascular Interventions | March 13, 2025 | Volume: 105 | Issue: 7 | Pages: 1535-1544

10.1002/ccd.31489 | PMID 40079618 Get It

ABSTRACTBackgroundMyeloproliferative neoplasms (MPN) are associated with an increased cardiovascular risk including acute coronary syndrome. However, there is a lack of comprehensive data regarding the rate of percutaneous coronary intervention (PCI), as well as the in‐hospital characteristics and outcomes for MPN patients.AimsWe aimed to evaluate the temporal trends and outcomes of PCI among patients with MPN.Methods and ResultsThe National Inpatient Sample database from 2016 to 2020 was queried to identify all PCI hospitalizations. Temporal trends and outcomes of patients with and without MPN following PCI were analyzed. Propensity score matching (PSM) was implemented to compare outcomes between MPN and non‐MPN groups. 2,237,210 PCI hospitalizations with 7560 (0.27%) patients with MPN were included in this study. Throughout the study period, the prevalence of MPN among PCI admissions remained stable (p‐value for trend = 0.12). Within the MPN subgroup, essential thrombocythemia (ET) was the predominant condition (53.2). Patients with MPN had higher prevalence of cardiovascular comorbidities than non‐MPN patients. Following PSM, MPNs were significantly associated with a higher risk of blood transfusions (OR: 1.66, 95% CI: 1.22−2.24, p = 0.001) and AKI (OR: 1.39, 95% CI: 1.17−1.65, p < 0.001). In contrast, the risk of in‐hospital mortality (OR: 1.18, 95% CI: 0.83−1.69, p = 0.354 and bleeding (OR: 1.43, 95% CI: 0.90−2.27, p = 0.127) did not significantly differ between the two groups.ConclusionsOur study demonstrated that while the prevalence of MPN among patients undergoing PCI remained stable, those with MPN faced higher risks of bleeding, blood transfusion and acute kidney injury. Further research is warranted to explore the underlying reasons for these increased risks and to improve outcomes in this high‐risk group.
Multicenter Experience With a Novel Real‐Time 3‐Dimensional Intracardiac Echocardiography Catheter to Guide Interventional Cardiac Procedures
Alkhouli, Mohamad , Carroll, John D. , Desai, Aken , Gao, Yu‐Rong , Xiong, Tomnema, Natale, Andrea , Inglessis‐Azuaje, Ignacio , Knight, Bradley P. , Alkhouli, Mohamad , Desai, Aken A , Knight, Bradley P , Natale, Andrea , Xiong, Tomnema

Mayo Clinic

Journal of the American Heart Association | March 13, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/jaha.124.037019 | PMID 40079298 Get It

Background Recent technologies enable real‐time 3‐dimensional intracardiac echocardiography (ICE) with the advantages of 2‐dimensional ICE and imaging capabilities of transesophageal echocardiography. The purpose of this study is to evaluate the real‐world, multicenter safety and performance of a novel 3‐dimensional ICE system in a variety of cardiac interventions used in standard clinical practice. Methods This prospective, multicenter, observational, single‐arm study enrolled patients who were scheduled for an invasive cardiac procedure involving guidance with ICE and followed until discharge or ≤48 hours postprocedure. Intracardiac imaging was performed with the 3‐dimensional ICE catheter, VeriSight Pro (Philips Inc.). Fluoroscopy was used in all cases and transesophageal echocardiography was used in some cases. The primary safety end point was device‐related adverse events. The primary efficacy end point included technical success, imaging success, and clinical success. Results Between October 2021 and November 2022, 155 patients were enrolled and screened. Percutaneous interventions performed included atrial septal defect/patent foramen ovale closures, left atrial appendage occlusion, catheter ablations, and valve procedures. No adverse events were related to the device or procedure. The technical, imaging, and clinical success rates were 98.7% (95% CI, 95.4%–99.8%), 96.1% (95% CI, 91.8%–98.6%), 94.8% (95% CI, 91.8%–98.6%), respectively. Overall, the VeriSight Pro ICE image quality was assessed to be “acceptable” or greater in relation to reference image modality among 96.2% (149 of 155) of procedures. Conclusions VeriSight ICE imaging is safe and effective in the guidance of a wide variety of percutaneous cardiovascular procedures and has provided successful and high‐quality imaging of cardiac structures.